Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection

Kyushu University Liver Disease Study (KULDS) Group

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and ontreatment predictors of bacterial infections in patients treated with TVR-based triple therapy. Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment. Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.

Original languageEnglish
Pages (from-to)567-572
Number of pages6
JournalInternal Medicine
Volume54
Issue number6
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Chronic Hepatitis C
Bacterial Infections
Infection
Therapeutics
Urinary Tract Infections
Serum Albumin
telaprevir
Ribavirin
Incidence
Interferons
Multicenter Studies
Logistic Models
Regression Analysis
Anti-Bacterial Agents
Inflammation
Bacteria

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection. / Kyushu University Liver Disease Study (KULDS) Group.

In: Internal Medicine, Vol. 54, No. 6, 01.01.2015, p. 567-572.

Research output: Contribution to journalArticle

Kyushu University Liver Disease Study (KULDS) Group. / Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection. In: Internal Medicine. 2015 ; Vol. 54, No. 6. pp. 567-572.
@article{6b64620d2f18449e9287c7fe0a1adbdb,
title = "Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection",
abstract = "Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and ontreatment predictors of bacterial infections in patients treated with TVR-based triple therapy. Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Results Bacterial infections occurred in 21 of the 430 (4.9{\%}) patients during TVR-based triple therapy. Among these subjects, 71.4{\%} (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8{\%} of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1{\%}) was significantly higher than that observed among men (1 of 215, 0.5{\%}) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8{\%}) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment. Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.",
author = "{Kyushu University Liver Disease Study (KULDS) Group} and Akira Kawano and Eiichi Ogawa and Norihiro Furusyo and Makoto Nakamuta and Eiji Kajiwara and Kazufumi Dohmen and Hideyuki Nomura and Kazuhiro Takahashi and Takeaki Satoh and Koichi Azuma and Yuichi Tanabe and Shinji Shimoda and Kazuhiro Kotoh and Jun Hayashi",
year = "2015",
month = "1",
day = "1",
doi = "10.2169/internalmedicine.54.3457",
language = "English",
volume = "54",
pages = "567--572",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "6",

}

TY - JOUR

T1 - Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection

AU - Kyushu University Liver Disease Study (KULDS) Group

AU - Kawano, Akira

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Nakamuta, Makoto

AU - Kajiwara, Eiji

AU - Dohmen, Kazufumi

AU - Nomura, Hideyuki

AU - Takahashi, Kazuhiro

AU - Satoh, Takeaki

AU - Azuma, Koichi

AU - Tanabe, Yuichi

AU - Shimoda, Shinji

AU - Kotoh, Kazuhiro

AU - Hayashi, Jun

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and ontreatment predictors of bacterial infections in patients treated with TVR-based triple therapy. Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment. Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.

AB - Objective There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy. This study was performed in order to evaluate the baseline and ontreatment predictors of bacterial infections in patients treated with TVR-based triple therapy. Methods This multicenter study evaluated 430 patients with chronic hepatitis C who received 12 weeks of TVR in combination with 24 weeks of pegylated interferon α2b plus ribavirin. The occurrence of a bacterial infection during anti-viral treatment was defined as the onset of local or systemic inflammation as a result of pathogenic bacteria. Results Bacterial infections occurred in 21 of the 430 (4.9%) patients during TVR-based triple therapy. Among these subjects, 71.4% (15 of 21) experienced bacterial infections during the initial eight weeks of treatment. Urinary tract infections were the most frequent infection, observed in 2.8% of cases (12 of 430). The rate of urinary tract infection among women (11 of 215, 5.1%) was significantly higher than that observed among men (1 of 215, 0.5%) (p<0.0001). According to a multivariable logistic regression analysis, the only significant independent predictor was the pretreatment serum albumin level (p=0.0008). Of the 21 patients who experienced bacterial infections, only one (4.8%) had to discontinue the treatment; however, the others were able to continue anti-viral treatment in combination with antibiotic treatment. Conclusion Clinicians should be concerned regarding the incidence of bacterial infections among patients treated with TVR-based triple therapy, especially those with a low serum albumin level.

UR - http://www.scopus.com/inward/record.url?scp=84926619364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926619364&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.54.3457

DO - 10.2169/internalmedicine.54.3457

M3 - Article

C2 - 25790806

AN - SCOPUS:84926619364

VL - 54

SP - 567

EP - 572

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 6

ER -